Komori
Financial results presentation4886ASKA Pharmaceutical Holdings Co.,Ltd.Pharmaceuticals

(Correction and Correction of Numerical Data) Regarding Partial Correction of the “Supplementary Materials for the First-Quarter Financial Results for the Fiscal Year Ending March 2026”

Regarding the supplementary materials for the first-quarter financial results released on 4 August 2025, sales of imported products by the Vietnamese subsidiary were changed from a gross basis to a net basis, reducing revenue and cost of sales by ¥1,680 million each. There was no impact on operating profit or other profit figures.

Worth reading
58In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
1680
¥ million
Wording
Definitive
How definitive the wording is.

What was corrected and how

A subsequent correction by the company to the contents of an already published filing.

Original disclosure4 August 2025

Supplementary Materials for the First-Quarter Financial Results for the Fiscal Year Ending March 2026

Open the original document
92 daysThe pre-correction wording stayed published for this period (Calculated from the Original Disclosure Date Indicated in the Document)
This correction2025-11-04
Location of correction (where in the original document)

売上高および売上原価の修正。訂正箇所が多数に及ぶため、訂正後の資料を添付し、訂正した個所は下線を付して表示

Changes売上高および売上原価がそれぞれ1,680百万円減少
Impact on Business Performance (the company’s explanation)

営業利益、経常利益および親会社株主に帰属する当期純利益等への影響はございません。

Reason for correction

Hataphar社の輸入品販売取引について、同社は顧客に移転する財またはサービスを支配しておらず、これらを手配するサービスのみを提供している「代理人」に該当する取引であると判断したため。会計方針に従い、顧客から受け取る額から商品の仕入先に支払う額を控除した純額で売上を計上する方法に訂正した。

What was corrected and how
ItemDetails
Disclosure subject to correctionSupplementary Materials for the First-Quarter Financial Results for the Fiscal Year Ending March 2026
Original disclosure date4 August 2025
Location of correction売上高および売上原価の修正。訂正箇所が多数に及ぶため、訂正後の資料を添付し、訂正した個所は下線を付して表示
Details of correction売上高および売上原価がそれぞれ1,680百万円減少
Reason for correctionHataphar社の輸入品販売取引について、同社は顧客に移転する財またはサービスを支配しておらず、これらを手配するサービスのみを提供している「代理人」に該当する取引であると判断したため。会計方針に従い、顧客から受け取る額から商品の仕入先に支払う額を控除した純額で売上を計上する方法に訂正した。
Impact on Business Performance営業利益、経常利益および親会社株主に帰属する当期純利益等への影響はございません。

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Hataphar社は顧客に移転する財またはサービスを支配しておらず、取引を手配する「代理人」に該当すると判断したため、会計方針に従い、売上を総額ではなく純額で計上する方法に訂正した。

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
(Correction and Correction of Numerical Data) Regarding Partial Correction of the “Supplementary Materials for the First-Quarter Financial Results for the Fiscal Year Ending March 2026” | ASKA Pharmaceutical Holdings Co.,Ltd. (4886) timely disclosure | Komori